Document text
Principal Investigator: Jacek Skarbinski
Organization: KAISER FOUNDATION RESEARCH INSTITUTE
Fiscal Year: 2024
Award: $302,796
Funding agency: National Cancer Institute
Abstract
Serologic testing for presence of SARS-CoV-2 antibodies is a critical tool for understanding the epidemiology
and designing control strategies for the COVID-19 pandemic. Our understanding of the epidemiology of this
pandemic is primarily derived from real-time data on the number of polymerase chain reaction (PCR)-positive
COVID-19 patients in outpatient and inpatient settings, and thus misses patients with asymptomatic infection or
who have not had SARS-CoV-2 PCR testing. Serologic testing for SARS-CoV-2 antibodies can identify
persons who have been exposed and infected with SARS-CoV-2 at any time and might be a correlate of
protective immunity. This project aims to advance our understanding of SARS-CoV-2 serological testing at the
individual and population-level. To achieve this we will develop and implement a large-scale, population-
based, flexible platform to assess SARS-CoV-2 sero-prevalence, sero-incidence, risk of sero-conversion and
longevity of antibody response in a large, integrated health system with linked rich demographic, behavioral
and clinical data. For Aim 1 we will establish a community cohort of Kaiser Permanente Northern California
(KPNC) members; a random sample of community dwelling persons, age 7 years and older, will be invited to
participate in ongoing surveillance of antibody development to assess population-level sero-prevalence and
sero-incidence. For Aim 2, we will enroll a cohort of persons who are positive for SARS-CoV-2 PCR or
antibodies and will follow them prospectively with repeat SARS-CoV-2 antibody testing for immune surveillance
and to determine longevity of antibody response. For Aim 3, we will establish a data-only cohort of all persons
who have been diagnosed with COVID-19 disease, or had SARS-CoV-2 PCR or antibody testing; As of July
15, 2020, there are about 290,000 such persons in KPNC and the number increases daily as we test ~10,000
persons per day. In this cohort, we will assess risk of SARS-CoV-2 re-infection and will have the opportunity to
examine interactions with a personal history of cancer or cancer treatment and other clinical factors or
comorbid conditions, to determine if these conditions influence the likelihood of development of COVID-19 or
reinfection. For Aim 4, we will establish mechanisms for collaboration with other scientists in the Serological
Sciences Network, including mechanisms for additional sample collection. This series of linked studies
embedded in a large, integrated health system with a large number of COVID-19 patients and high SARS-
CoV-2 testing capacity will enhance our understanding of the utility of commercially available, large-scale
SARS-CoV-2 antibody testing for population-level and individual-level disease control.
Terms: <2019 novel corona virus><2019 novel coronavirus><2019-nCoV><7 year old><7 years of age><Active Follow-up><Address><Antibodies><Antibody Response><Assay><Behavioral><Bioassay><Biological Assay><COVID crisis><COVID diagnosis><COVID epidemic><COVID incidence><COVID infected patient><COVID pandemic><COVID patient><COVID positive patient><COVID testing><COVID-19><COVID-19 antibody><COVID-19 case incidence><COVID-19 crisis><COVID-19 diagnosis><COVID-19 disease incidence><COVID-19 epidemic><COVID-19 era><COVID-19 exposure><COVID-19 global health crisis><COVID-19 global pandemic><COVID-19 health crisis><COVID-19 incidence><COVID-19 infected patient><COVID-19 infection><COVID-19 pandemic><COVID-19 patient><COVID-19 period><COVID-19 positive><COVID-19 positive patient><COVID-19 positivity><COVID-19 public health crisis><COVID-19 related risk><COVID-19 risk><COVID-19 risk factor><COVID-19 testing><COVID-19 virus><COVID-19 virus infection><COVID-19 years><COVID19 diagnosis><COVID19 infection><COVID19 patient><COVID19 positive patient><COVID19 testing><COVID19 virus><CV-19><California><Cancer Treatment><Cancers><Characteristics><China><Clinical><Clinical Data><CoV-2><CoV2><Collaborations><Collection><Communicable Diseases><Communities><Complement><Complement Proteins><Coronavirus Infectious Disease 2019><Data><Data Sources><Development><Dimensions><Disease><Disease Surveillance><Disorder><Electronic Health Record><Enrollment><Epidemiology><Ethnic Origin><Ethnicity><Evaluation><Health system><History><Immune Surveillance><Immunity><Immunologic Surveillance><Immunologic Surveillances><Immunologic Tests><Immunological Surveillance><Immunological Surveillances><Immunological Tests><Immunosurveillance><Incidence><Individual><Infection><Infectious Disease Pathway><Infectious Diseases><Infectious Disorder><Infrastructure><Inpatients><Integrated Health Care Systems><Length of Life><Link><Longevity><Mainland China><Malignant Neoplasm Therapy><Malignant Neoplasm Treatment><Malignant Neoplasms><Malignant Tumor><Medical Records><Morbidity><Morbidity - disease rate><Out-patients><Outcome><Outpatients><Patients><Persons><Polymerase Chain Reaction><Population><Population Heterogeneity><Prevalence><Prospective Studies><Prospective, cohort study><Protocol><Protocols documentation><Race><Races><Recording of previous events><Recurrence><Recurrent><Risk><Risk Assessment><SARS corona virus 2><SARS-CO-V2><SARS-COVID-2><SARS-CoV-2><SARS-CoV-2 antibody><SARS-CoV-2 diagnosis><SARS-CoV-2 epidemic><SARS-CoV-2 exposure><SARS-CoV-2 global health crisis><SARS-CoV-2 global pandemic><SARS-CoV-2 incidence><SARS-CoV-2 infected patient><SARS-CoV-2 infection><SARS-CoV-2 pandemic><SARS-CoV-2 patient><SARS-CoV-2 positive><SARS-CoV-2 positive patient><SARS-CoV-2 positivity><SARS-CoV-2 testing><SARS-CoV2><SARS-CoV2 exposure><SARS-CoV2 infection><SARS-associated corona virus 2><SARS-associated coronavirus 2><SARS-coronavirus-2><SARS-coronavirus-2 epidemic><SARS-coronavirus-2 pandemic><SARS-related corona virus 2><SARS-related coronavirus 2><SARSCoV2><Sample Size><Sampling><Science><Scientist><Series><Serology><Serology test><Seroprevalences><Severe Acute Respiratory Coronavirus 2><Severe Acute Respiratory Distress Syndrome CoV 2><Severe Acute Respiratory Distress Syndrome Corona Virus 2><Severe Acute Respiratory Distress Syndrome Coronavirus 2><Severe Acute Respiratory Syndrome CoV 2><Severe Acute Respiratory Syndrome CoV 2 epidemic><Severe Acute Respiratory Syndrome CoV 2 pandemic><Severe Acute Respiratory Syndrome-associated coronavirus 2><Severe Acute Respiratory Syndrome-related coronavirus 2><Severe acute respiratory syndrome associated corona virus 2><Severe acute respiratory syndrome coronavirus 2><Severe acute respiratory syndrome coronavirus 2 epidemic><Severe acute respiratory syndrome coronavirus 2 exposure><Severe acute respiratory syndrome coronavirus 2 infection><Severe acute respiratory syndrome coronavirus 2 pandemic><Severe acute respiratory syndrome coronavirus 2 positive><Severe acute respiratory syndrome coronavirus 2 positivity><Severe acute respiratory syndrome related corona virus 2><Shelter facility><System><Testing><Time><Variant><Variation><Viremia><Wuhan coronavirus><active followup><age 7 years><aged><anti-cancer therapy><antibody against COVID-19><antibody against SARS-CoV-2><antibody against coronavirus disease 2019><antibody against severe acute respiratory syndrome coronavirus 2><antibody to COVID-19><antibody to SARS-CoV-2><antibody to coronavirus disease 2019><antibody to severe acute respiratory syndrome coronavirus 2><assess effectiveness><cancer therapy><cancer-directed therapy><care seeking><co-morbid><co-morbidity><cohort><comorbidity><complementation><coronavirus diagnosis><coronavirus disease 2019><coronavirus disease 2019 antibody><coronavirus disease 2019 crisis><coronavirus disease 2019 diagnosis><coronavirus disease 2019 epidemic><coronavirus disease 2019 exposure><coronavirus disease 2019 global health crisis><coronavirus disease 2019 global pandemic><coronavirus disease 2019 health crisis><coronavirus disease 2019 infected patient><coronavirus disease 2019 infection><coronavirus disease 2019 pandemic><coronavirus disease 2019 patient><coronavirus disease 2019 positive><coronavirus disease 2019 positive patient><coronavirus disease 2019 positivity><coronavirus disease 2019 public health crisis><coronavirus disease 2019 risk><coronavirus disease 2019 risk factor><coronavirus disease 2019 testing><coronavirus disease 2019 virus><coronavirus disease crisis><coronavirus disease diagnosis><coronavirus disease epidemic><coronavirus disease infected patient><coronavirus disease pandemic><coronavirus disease patient><coronavirus disease positive patient><coronavirus disease testing><coronavirus disease-19><coronavirus disease-19 global pandemic><coronavirus disease-19 pandemic><coronavirus disease-19 patient><coronavirus disease-19 virus><coronavirus infectious disease-19><coronavirus patient><coronavirus testing><design><designing><determine effectiveness><developmental><diagnosed with COVID><diagnosed with COVID-19><diagnosed with COVID19><diagnosed with SARS-CoV-2><diagnosed with coronavirus><diagnosed with coronavirus 2019><diagnosed with coronavirus disease><diagnosed with coronavirus disease 2019><disease control><disorder control><diverse populations><effectiveness assessment><effectiveness evaluation><electronic health care record><electronic health medical record><electronic health plan record><electronic health registry><electronic medical health record><enroll><epidemiologic><epidemiological><evaluate effectiveness><examine effectiveness><exposure to COVID-19><exposure to SARS-CoV-2><exposure to SARS-CoV2><exposure to Severe acute respiratory syndrome coronavirus 2><exposure to coronavirus disease 2019><flexibility><flexible><follow up><follow-up><followed up><followup><hCoV19><heterogeneous population><high risk group><high risk individual><high risk people><high risk population><histories><incidence rates of SARS-CoV-2 infection><incident cases of SARS-CoV-2><infected with COVID-19><infected with COVID19><infected with SARS-CoV-2><infected with SARS-CoV2><infected with coronavirus disease 2019><infected with severe acute respiratory syndrome coronavirus 2><integrated health system><integrated healthcare systems><integrated system of care><malignancy><member><mortality><nCoV2><neoplasm/cancer><pandemic><pandemic disease><patient infected with COVID><patient infected with COVID-19><patient infected with SARS-CoV-2><patient infected with coronavirus disease><patient infected with coronavirus disease 2019><patient infected with severe acute respiratory syndrome coronavirus 2><patient with COVID><patient with COVID-19><patient with COVID19><patient with SARS-CoV-2><patient with coronavirus disease><patient with coronavirus disease 2019><patient with severe acute respiratory distress syndrome coronavirus 2><population based><population diversity><prospective><racial><racial background><racial origin><risk associated with COVID-19><risk factor associated with COVID-19><risk factor related to COVID-19><risk related to COVID-19><sample collection><seroconversion><serology assay><serology surveillance><seropositive><serosurveillance><seven year old><seven years of age><severe acute respiratory syndrome coronavirus 2 antibody><severe acute respiratory syndrome coronavirus 2 diagnosis><severe acute respiratory syndrome coronavirus 2 global health crisis><severe acute respiratory syndrome coronavirus 2 global pandemic><severe acute respiratory syndrome coronavirus 2 infected patient><severe acute respiratory syndrome coronavirus 2 patient><severe acute respiratory syndrome coronavirus 2 positive patient><severe acute respiratory syndrome coronavirus 2 testing><shelter><shelter housing><shelters><specimen collection><testing for COVID><testing of COVID><tool><viraemia><viral sepsis><virusemia>